IQuum was acquired by Roche Group on April 2014. IQuum is developing lab-in-a-tube technology, a novel biological sample testing platform which provides revolutionary benefits to a broad cross section of the bioassay market. The Company's proprietary technology enables the non-specialized personnel to perform more sophisticated biological sample testing in any setting with greater speed. Company is commercializing its lab-in-a-tube technology and products for the clinical diagnostics, bio-defense, and industrial testing markets. d growth and expansion of IQuum. In Dec 2006, firm had been awarded $3.8 million contract from the Centers for Disease Control and Prevention (CDC) for the development of rapid point-of-care (POC) diagnostics for avian influenza.
